title: The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
abstract: Type III hyperlipoproteinemia (type III HLP) is an atherogenic disorder of lipoprotein metabolism characterized by the accumulation of cholesterol-enriched VLDL and is usually associated with homozygosity for a normal variant of apoE, apoE2. ApoE2(Arg145Cys) is a rare variant arising from a C-->T transition at nucleotide 4031 and has been linked to type III HLP. Ten subjects from a group of 42 unrelated individuals with proven type III HLP were found to be either heterozygous or homozygous for the apoE2(Arg145Cys) mutation by DNA sequencing. The apoE4-Philadelphia (Glu13Lys, Arg145Cys) variant was subsequently excluded. None of 4 homozygotes (3 blacks and 1 of mixed ancestry) developed ischemic heart disease, but they did present with xanthomata. In contrast, 6 heterozygous subjects presented mainly with ischemic heart disease but generally lacked physical signs. Cholesterol concentrations ranged from 6.2 mmol/L to 13.3 mmol/L and triglyceride levels from 3.2 to 13.2 mmol/L. The dyslipoproteinemia in homozygous and heterozygous subjects was indistinguishable. Family investigation identified an additional 10 heterozygous mutant-allele carriers, of whom 3 had type III HLP. This unique cohort of patients indicates that the apoE2(Arg145Cys) mutation is relatively common in several population groups in our region and may be particularly prevalent in blacks. There was no clear allele dosage effect present for the development of dyslipoproteinemia or atherosclerosis. The mode of inheritance is for the first time clearly established to be autosomal dominant with incomplete penetrance.
authors.affiliation: Department of Medical Biochemistry, University of Cape Town Medical School, South Africa.
authors.forename: W J
authors.initials: WJ
authors.lastname: de Villiers
authors.forename: D R
authors.initials: DR
authors.lastname: van der Westhuyzen
authors.forename: G A
authors.initials: GA
authors.lastname: Coetzee
authors.forename: H E
authors.initials: HE
authors.lastname: Henderson
authors.forename: A D
authors.initials: AD
authors.lastname: Marais
mesh_terms: D000293:Adolescent; D000328:Adult; D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000235:genetics*; D001120:Arginine; D008076:Cholesterol, HDL / Q000097:blood; D003545:Cysteine; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006951:Hyperlipoproteinemias / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D015183:Restriction Mapping; D017422:Sequence Analysis, DNA; D014280:Triglycerides / Q000097:blood
chemical_list: D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D014280:Triglycerides; D001120:Arginine; D003545:Cysteine